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Abstract
Background: There are few validated tools to measure adherence for children living with HIV.We identified questionnaire items
for caregivers of Kenyan children aged <15 years living with HIV.Methods: Caregiver–child dyads were followed for 6 months.
At monthly visits, the child’s HIV provider administered a 10-item questionnaire to the caregiver. Children were given electronic
dose monitors (Medication Event Monitoring Systems [MEMS]). Correlation between questionnaire items and dichotomized
MEMS adherence (90% doses taken versus <90%) was investigated using logistic regression models. Results: In 95 caregiver–
child dyads, mean age of children (40% female) was 8.3 years. Items associated with higher odds of MEMS adherence in
multivariable analysis included the father giving the child medication, being enrolled in a nutrition program, and the caregiver
reporting no difficulties giving the child medication. Conclusion: Providers typically ask about missed doses, but asking about
caregiver responsibilities and difficulties in giving the child medication may better detect suboptimal adherence.
Keywords
HIV-infected children, adherence to treatment, Kenya, validation testing
Introduction
Despite significant progress in the prevention of mother-to-
child transmission, there are an estimated 1.8 million children
younger than 15 years living with human immunodeficiency
virus (HIV), including an estimated 150 000 newly infected
children in 2015.1 Moreover, only 49% of children in need of
antiretroviral therapy (ART) had access to it.1 For those chil-
dren accessing life-saving ART, consistent and long-term
adherence is required to reduce morbidity and mortality and
to prevent drug resistance.2-5 High levels of adherence to ther-
apy are even more important for the vast majority of children
living with HIV in resource-poor settings where access to sec-
ond- and third-line regimens is still limited.6,7 Children in these
settings face multiple and complex barriers to access and
adherence to treatment, and there are few data to inform
evidence-based interventions.8
There is no gold standard for clinical evaluation of adher-
ence to ART.9 Estimates of ART adherence among children are
hampered by heterogeneous and untested measures.10,11 The
reliability of caregiver-reported missed doses, one of the most
commonly employed adherence measures, has been evaluated
in the United States12,13 and in several sub-Saharan African
countries14-16 and suggests that caregivers may overestimate
adherence compared to other measures like pill counts, phar-
macy refill, and electronic adherence monitoring (EAM), but
most studies do not report on validity testing of the measure. A
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validated caregiver-reported adherence tool by the NIAID
Pediatric Clinical Trials Group demonstrated high correlation
with virologic outcomes among children in the United States,17
but how this measure performs in resource-limited settings is
unclear.
Access to accurate and low-cost tools to routinely measure
adherence to ART among children living with HIV is critical to
guide clinical decision-making, reduce the risk of drug resis-
tance, and evaluate adherence interventions.18 Previously, we
examined 48 adherence questionnaire items using EAM as our
external criterion for adherence among caregivers of HIV-
infected children in care at clinics of the Academic Model
Providing Access to Healthcare (AMPATH) in western
Kenya.19 Using the adherence items that were most associated
with EAM to create a 10-item questionnaire, in this study, we
test the reliability and validity of the shortened adherence mea-
sure among a new cohort of children living with HIV and on
ART in Kenya.
Methods
Study Design
We conducted a multistage validation study using prospective
cohorts of Kenyan children living with HIV to evaluate the
performance of questionnaire items to estimate ART adher-
ence. During a previous stage, we created 48 pediatric ART
adherence questionnaire items informed by literature review,
expert panel consultation, and formal qualitative work
including individual and group cognitive assessments of ques-
tionnaire items in this setting in western Kenya.20,21 These
adherence items, which included questions related to missed
doses, doses taken by visual analog scale, adherence barriers,
and other social factors such as poverty and HIV stigma, were
translated into Kiswahili, one of the national languages of
Kenya, with good understandability and face validity.20 We
tested the 48 items among 200 caregiver–child dyads, who
were prospectively followed for 6 months with the adherence
items being administered to the caregiver at monthly visits, as
well as to children who were responsible for their own
medication-taking (48-item adherence questionnaire included
in Online Appendix).19 Participants kept their ART in bottles
containing Medication Event Monitoring Systems (MEMS;
MWV/AARDEX Ltd, Seraign, Belgium, Switzerland) caps
that have a microcircuit that records the time and date of bottle
opening and shows good correlation with virologic out-
comes.22,23 Using a novel variable selection strategy called
least absolute shrinkage and selection operator with logistic
regression, we identified the adherence items best correlated
with MEMS adherence.19
In this study, we conducted a prospective assessment of the
10 best–performing adherence items from our previous study.
We followed 107 caregiver–child dyads for 6 months to test the
reliability and validity of the 10-item adherence questionnaire
to measure children’s adherence to ART. The questionnaire
was administered to caregivers at baseline and monthly visits
(a total of 7 times) in Kiswahili or English (dependent on
caregiver’s preference) by their child’s regular clinician (phy-
sician or clinical officer) as part of their routine monthly clin-
ical exams. A child version of the questionnaire was also
administered to children if they or their caregiver reported that
the child had responsibility for their own medication-taking;
however, low response rate and other difficulties precluded
robust analysis (see “Discussion” section). In addition, we
administered the original 48-item questionnaire (inclusive of
the 10 best–performing items that are tested in this study) to
caregivers at baseline, month 3, and month 6. This was done to
allow comparison of caregiver responses to the same 10 adher-
ence items at these time points based on 2 key differences: (1) a
different format (ie, longer form versus shorter form) and (2) by
who was administering the questionnaire (clinician or research
assistant). As done in the previous study,19 the longer 48-item
questionnaire was administered to the caregiver by research
personnel immediately after the child’s visit with the physician.
Participants were issued MEMS monitoring devices and
instructed in their care and use during the follow-up period,
with study personnel downloading and inspecting the MEMS at
monthly study visits. Children had blood samples taken at
month 3 and month 6 of the study to evaluate immunological
status (CD4 counts and percentages).
Study Setting
This study took place at AMPATH—a large HIV treatment
program in western Kenya.24,25 The AMPATH is a partnership
What Do We Already Know about This Topic?
Adherence monitoring is an essential component of com-
prehensive HIV care and management, yet there are few
low-cost, validated instruments to measure adherence for
children and adolescents living with HIV in sub-Saharan
Africa.
How Does Your Research Contribute to the
Field?
We tested the validity of a short 10-item adherence ques-
tionnaire administered to children’s caregivers in western
Kenya and showed that the instrument could be used by
HIV providers as a screening tool for nonadherence
among children living with HIV and on treatment.
What Are Your Research’s Implications toward
Theory, Practice, or Policy?
Our research supports the feasibility of validated, low-
cost, and routine adherence monitoring tools such as brief
questionnaires for children living with HIV and on treat-
ment as part of comprehensive HIV care and management.
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between Moi University School of Medicine, Moi Teaching
and Referral Hospital (MTRH), and a consortium of North
American academic medical centers led by Indiana University
School of Medicine. The AMPATH provides free ART (first-
and second-line ART regimens only), primary care services,
and psychosocial and nutritional support for children and adults
at over 50 health clinics in western Kenya. This study recruited
participants from AMPATH’s clinic at MTRH, one of the larg-
est referral hospitals in Kenya located in the city of Eldoret in
Uasin Gishu County, Rift Valley Province.
Study Participants
Inclusion criteria for children were HIV infected, between 0
and 14 years of age, on a first-line ART regimen, and enrolled
in care at AMPATH. Children’s current adherence level was
not considered in their inclusion in the study—that is, we
wanted to recruit children with a range of adherence levels to
test the reliability and validity of the questionnaire. Caregivers
were biological or nonbiological caregivers who accompanied
the child to clinic, were knowledgeable about the child’s med-
ical needs, and had at least some responsibility for administer-
ing or supervising their child’s medication-taking. The same
caregiver was encouraged to come to all of the child’s study
visits during the follow-up period, but we did not exclude
different caregivers from completing the adherence question-
naire. Participants were recruited using convenience sampling;
eligible caregiver–child dyads were identified by clinic and
research personnel and referred to the study team for partici-
pation. Informed consent was obtained from all caregivers for
their own and their child’s participation in the study. Assent
was obtained for all children aged 10 years and older, consis-
tent with AMPATH research protocols. A small incentive
(<US$3) was provided to study participants to cover their trans-
portation costs and time.
Data Analysis
Basic demographics are presented with means (standard devia-
tions [SD]) for continuous variables and frequencies (percen-
tages) for categorical variables. Demographic variables were
compared by adherence groups using Student t tests and Fisher
exact tests, due to low cell counts, respectively.
Electronic adherence outcomes were dichotomized as
90% of doses taken on schedule (defined as “adherent”) or
<90% for analysis (defined as “nonadherent”). Dichotomized
adherence at 90% cutoff was used alongside sensitivity analy-
ses for a number of reasons. Continuous adherence data were
highly skewed, with a prevalent ceiling effect due to children
clustering around the maximal level of 100% adherence. A
90% cutoff point was chosen as it has been used in similar
studies26,27 and because of its clinical relevance; studies show
that adherence rates <90% are associated with increased risk
for virologic failure and drug resistance.28-30 Demographic and
clinical characteristics of study participants were summarized
by dichotomized MEMS adherence level. Individual items in
caregiver questionnaire were then screened by bivariate
logistic regression models of the dichotomized MEMS adher-
ence outcome. Items associated with the adherence at P <.05
were selected for the multivariable logistic regression models.
In all these analyses, within-subject correlations among
repeated measures were accommodated by generalized esti-
mating equations; odds ratios (ORs) and 95% confidence inter-
vals (95% CIs) are reported, with an OR >1.00 indicating a
higher odds of MEMS adherence.
Selected caregiver items were then used to form an adher-
ence barrier scale. We assessed the classification accuracy of
the scale using Cox-Snell R2 values. These were calculated at
both visits 3 and 6, as well as both visits combined. To increase
the robustness of the analysis, sensitivity analyses were con-
ducted at different MEMS adherence cutoff points at 80% and
95% adherence levels.31 Statistical analyses were performed
using R 3.0.1 (Vienna, Austria) and SAS v9.4 (SAS Institute,
Cary, North Carolina). P values less than .05 are considered
statistically significant.
Research Ethics and Informed Consent
This study was approved by the institutional review board at
Indiana University School of Medicine in Indianapolis, Indiana
(IRB study number: 0904-67) and by the Institutional Research
and Ethics Committee at Moi University School of Medicine in
Eldoret, Kenya (IREC study number: 2009/61).
Results
Participant Characteristics
We recruited 107 caregiver–child dyads, of which 95 attended
all study evaluations and had complete adherence and clinical
data. Of these 95 caregiver–child dyads, mean age of children
was 8.32 years (SD: 3.27) and 40.4% were female (Table 1).
From baseline, the child’s most recent mean CD4 percentage
(CD4%) was 27.76 (SD: 10.16) and the majority of children
had advanced clinical disease (67% of children were diagnosed
at World Health Organization stage 3 or 4 disease). A small
minority of children (14%) knew their HIV status. There were
no significant differences in child characteristics in the adher-
ent (MEMS 90% doses taken) compared to the nonadherent
group (MEMS <90% doses taken). On average, nonadherent
children were on ART for longer duration (6.7 years compared
to 3.6 years), but this was not statistically significant (P ¼ .08).
The majority of caregivers who participated in the study were
the biological mother of the child (59%), while an uncle, aunt,
or cousin was the second most common type of caregiver
(15%). The biological mother was also the one most often
responsible for giving the child his or her medicines (55%),
although 17% also reported that the child is responsible for his
or her own medication-taking.
Adherence by MEMS increased significantly over the dura-
tion of the study; at month 1, mean and median adherence by
MEMS was 83% and 94%, respectively, while by month 6, this
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had increased to 91% and 96%, respectively (P ¼ .005). The
increase in adherence over time was more marked in the group
of patients with <90% MEMS, as illustrated in Figure 1. Still,
when MEMS adherence was calculated over the course of the
study, just over half of participants (52%) achieved 90% of
doses taken.
Validation Testing of Questionnaire
The short-form adherence questionnaire performed well. Intra-
class correlation coefficient analysis showed that the intraclass
correlations were similar between the short-form adherence
questionnaire items used in this study and the long-form adher-
ence questionnaire tested previously, indicating no significant
loss of information. Intraclass correlations were 0.316 at
3 months and 0.322 at 6 months, with overlapping CIs.
Table 1. Caregiver–Child Dyad Characteristics by MEMS Adherent Group at Baseline Visit.
Characteristic
Overall,
N ¼ 95
Adherent Group (MEMS 90%
Doses Taken), N ¼ 49 (51.6%)
Nonadherent Group (MEMS <90%
Doses Taken), N ¼ 46 (48.4%)
P
Value
Child characteristics
Mean age (years) 8.32 (3.27) 8.59 (3.35) 8.04 (3.20) .413
Female 38 (40.4%) 16 (33.3%) 22 (47.8%) .207
Mean weight-for-age Z (WAZ) score 1.49 (1.29) 1.72 (1.27) 1.26 (1.28) .090
Mean ART duration (years) 5.15 (8.25) 3.66 (4.84) 6.70 (10.55) .079
Mean CD4% 27.76 (10.16) 28.30 (10.15) 27.21 (10.26) .624
Absolute CD4 929 (559) 946 (620) 911 (494) .774
WHO stage .764
1 13 (14.4%) 5 (11.4%) 8 (17.4%)
2 17 (18.9%) 9 (20.5%) 8 (17.4%)
3 52 (57.8%) 25 (56.8%) 27 (58.7%)
4 8 (8.9%) 5 (11.4%) 3 (6.5%)
Disclosed (ie, child knows his or her
HIV status)
11 (13.8%) 5 (11.9%) 6 (15.8%) .749
Caregiver and/or family characteristics
Caregiver relationship to child
Mother 56 (59.0%) 30 (61.2%) 26 (56.5%) .680
Father 4 (4.2%) 3 (6.1%) 1 (2.2%) .618
Sibling 3 (3.2%) 0 (0%) 3 (6.5%) .110
Grandparent 2 (2.1%) 1 (2.0%) 2 (2.2%) 1.000
Stepparent 1 (1.1%) 1 (2.0%) 0 (0%) 1.000
Uncle/aunt/cousin 14 (14.7%) 8 (16.3%) 6 (13.0%) .775
Other 8 (8.4%) 2 (4.1%) 6 (13.0%) .151
Caregiver who gives the child his or
her medication
Mother 52 (54.7%) 24 (49.0%) 28 (60.9%) .304
Father 8 (8.4%) 5 (10.2%) 3 (6.5%) .716
Sibling 7 (7.4%) 1 (2.0%) 6 (13.0%) .054
Grandparent/uncle/aunt 13 (13.7%) 7 (14.3%) 6 (13.0%) 1.000
Other 5 (5.3%) 5 (10.2%) 0 (0%) .057
Child takes medication 16 (16.8%) 8 (16.3%) 8 (17.4%) 1.000
Enrolled in AMPATH’s nutrition
program (n)
9 (10.1%) 5 (10.9%) 4 (9.3%) 1.000
Mean number of people in the household
who take medicines for HIV
1.96 (1.04) 2.07 (1.19) 1.85 (0.84) .327
Abbreviations: AMPATH, Academic Model Providing Access to Healthcare; ART, antiretroviral therapy; MEMS, Medication Event Monitoring Systems; WHO,
World Health Organization.
Figure 1. Adherence by Medication Event Monitoring Systems
(MEMS).
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Cox-Snell R2 values were also similar (visit 3: 0.037 versus
0.005; visit 6: 0.020 versus 0.011; both: 0.002 versus 0.008, for
short form versus long form, respectively). Likelihood ratio
tests indicate the values are not significantly different when
comparing the short form to the long form.
In bivariate analysis, most of the questionnaire items were
significantly associated with dichotomized MEMS adherence
including items directly related to missed doses and problems
with adherence as well as items related to the type of caregiver
and who was responsible for giving the child his or her medica-
tion (Table 2). In subanalyses, we found that items performed
similarly well between children who received ART from their
mother versus those who received ART from a different care-
giver. In children who received ART from their mothers,
reporting the child was disclosed to was significantly associ-
ated with a lower odds of MEMS adherence (OR: 0.66, 95%
CI: 0.59-0.73), while in children who received ART from
someone other than their mothers, it was nonsignificantly asso-
ciated with a higher odds of MEMS adherence (OR: 1.32, 95%
CI: 0.91-1.92).
In multivariate analysis, the biological father (OR: 1.4, 95%
CI: 1.2-1.7) or a nonbiological family member (OR: 1.3, 95%
CI: 1.2-1.5) being responsible for giving the child ART
were both significantly associated with high odds of being in
the MEMS adherent group (Table 3). Being enrolled in the
AMPATH nutrition program was also associated with higher
odds of being in the MEMS adherent group (OR: 1.3, 95% CI:
1.0-1.6). Finally, the caregiver reporting problems getting the
child to take ART (OR: 0.7, 95% CI: 0.6-0.8) and reporting
problems giving ART on time (OR: 0.9, 95% CI: 0.8-1.0) were
associated with lower odds of being in the MEMS adherent
group. While the caregivers reporting that the child took a dose
more than 1 hour late (P ¼ .0002) and that the child missed at
least 1 dose in the past 7 days (P ¼ .0078) were significant in
bivariate analysis, late and missed doses in the past 7 days did
not remain significant in the multivariate model.
Discussion
The 10-item adherence questionnaire administered to care-
givers of children living with HIV performed well when vali-
dated against EAM. Of the 10 questionnaire items, 7 were
significantly associated with dichotomized MEMS adherence
in bivariate analysis, while 4 of these items remained statisti-
cally significant in multivariate analysis. While low-cost and
Table 2. Unadjusted Associations between Questionnaire Items and
Medication Adherence Measured by MEMS.
Caregiver–Reported Adherence
Questionnaire Item OR (95% CI) P Value
Caregiver primarily responsible for giving
the child ART
Mother 1.04 (0.92-1.19) .514
Father 1.30 (1.09-1.55) .003
Grandparent/aunt/uncle 0.96 (0.75-1.22) .714
Guardian/neighbor/relative/help/other 1.49 (1.34-1.65) <.001
Sibling 0.86 (0.70-1.05) .145
Child him- or herself 0.91 (0.75-1.11) .335
Caregiver relationship to child
Mother 1.01 (0.90-1.14) .842
Father 1.23 (0.97-1.57) .085
Stepparent 1.40 (1.16-1.68) <0.001
Grandparent 0.84 (0.66-1.07) .157
Sibling 0.86 (0.71-1.05) .139
Aunt/uncle 1.00 (0.82-1.22) .966
Other 1.02 (0.88-1.19) .751
Enrolled in AMPATH’s nutrition support
program
1.25 (1.02-1.54) .0340
Child disclosed (ie, child knows his or her
HIV status)
1.17 (0.93-1.47) .176
Caregiver had difficulty giving ART to the
child on time
0.87 (0.78-0.96) .009
Caregiver had difficulty in general giving
ART to the child
0.61 (0.50-0.75) <.001
At least 1 other person (in addition to
child) in the household has HIV and
takes ART
1.00 (0.97-1.03) .989
Caregiver reported that child missed at
least 1 dose of ART in the past 7 days
0.95 (0.91-0.99) .008
Caregiver reported that child took at least
1 dose of ART more than 1 hour late in
the past 7 days
0.96 (0.94-0.98) <.001
Caregiver reported that the child missed
at least 1 dose of ART in the past month
0.99 (0.93-1.05) .730
Abbreviations: AMPATH, Academic Model Providing Access to Healthcare;
ART, antiretroviral therapy; CI, confidence interval; MEMS, Medication Event
Monitoring Systems; OR, odds ratio.
Table 3. Adjusted Associations between Questionnaire Items and
Medication Adherence Measured by MEMS.
Caregiver–Reported Adherence
Questionnaire Item OR (95% CI) P Value
Caregiver primarily responsible for giving
the child ART?
Father 1.43 (1.20-1.72) .001
Guardian/neighbor/relative/help/other 1.34 (1.18-1.53) <.001
Caregiver relationship to the child?
Father 0.87 (0.68-1.10) .243
Stepparent 1.16 (0.93-1.45) .185
Enrolled in AMPATH’s nutrition support
program
1.25 (1.00-1.57) .049
Child disclosed (ie, child knows his or her
HIV status)
0.86 (0.68-1.09) .203
Caregiver had difficulty giving ART to the
child on time
0.88 (0.77-1.00) .043
Caregiver had difficulty in general giving
ART to the child
0.67 (0.58-0.79) <.001
Caregiver reported that child missed at
least 1 dose of ART in the past 7 days
0.96 (0.92-1.01) .137
Caregiver reported that child took at least
1 dose of ART more than 1 hour late in
the past 7 days
0.98 (0.95-1.01) .229
Abbreviations: AMPATH, Academic Model Providing Access to Healthcare;
ART, antiretroviral therapy; CI, confidence interval; MEMS, Medication Event
Monitoring Systems; OR, odds ratio.
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routine adherence monitoring has been highlighted as a criti-
cally important part of comprehensive HIV care, there have
been few studies that have rigorously validated adherence
questionnaire items in low-income settings, particularly for
children living with HIV. This study adds to the limited
research base and offers a set of potential adherence question-
naire items to be evaluated in other resource-limited settings.
We are currently evaluating the performance of this 10-item
adherence questionnaire at an additional site in western Kenya,
as well as at sites in South Africa and Thailand.
As in previous work,19 we found that a broad range of ques-
tionnaire items were associated with children’s adherence.
While most routine self-reported adherence assessment items
ask about missed doses during a specific period (eg, in the past
3, 7, or 30 days),10 our analysis showed that questions other
than missed doses may be a better indication of potential prob-
lems with adherence, particularly for assessing the adherence
of children living with HIV who are often not responsible for
their own medication-taking. This includes questions related to
who in the household is responsible for giving the child ART.
Our findings indicated that when the child’s father or nonbio-
logical caregiver was responsible for giving the child ART, the
child was more likely to have MEMS adherence 90%. We
also found that when a child’s mother was responsible for
giving the child ART, the child knowing his or her HIV status
was significantly associated with lower odds of MEMS adher-
ence 90%, but for a child who was given ART by any other
type of caregiver or responsible for their own medication-
taking, knowing his or her HIV status was associated with
higher odds of MEMS adherence 90%, although this was not
statistically significant. Qualitative inquiry in this setting will
shed light on why caregiver type impacts children’s adherence
in western Kenya; however, for clinicians and other providers,
the important finding here is that questions related to the care-
giver should be part of the adherence assessment. In previous
work, we found that if a child’s primary caregiver was
employed outside the house, the child was more likely to have
poorer adherence, further suggesting caregiver-related
dynamics in adherence behaviors for HIV-infected children.31
In addition, we found that questions related to general prob-
lems with giving a child ART and problems related to medica-
tion timing were more likely to be associated with suboptimal
adherence by electronic monitoring versus questions directly
related to missed or late doses over the past 7 or 30 days. This
finding may reflect caregiver unwillingness to admit subopti-
mal adherence to providers due to fear of stigma, embarrass-
ment, or punishment. Studies from various settings have
illustrated the importance of a positive patient–provider rela-
tionship in facilitating good adherence,32 but there has been
less work done among caregivers of young children living with
HIV.33 Caregivers may feel additional social pressure to report
adherence to providers. Another possibility is that the caregiver
answering the questionnaire is not the sole person responsible
for giving the child ART, and thus, while the caregiver might
be knowledgeable about general problems, he or she may not
have knowledge about specific instances of missed doses.
The study protocol called for administering the adherence
questionnaire items to children who had responsibility for their
own medication-taking. As this was a younger cohort, the total
number of children who responded to questionnaire items was
low, which precluded robust analysis of child-reported items
and their association with EAM. In addition, there was diffi-
culty in assessing whether a child had responsibility for his or
her medication-taking, which was also related to the child’s
disclosure status; asking children questions about ART, even
generally, may be considered risky or inappropriate by care-
givers or clinicians when the child does not know they are HIV
infected. Additional work is needed on how to solicit child
perspectives in adherence assessment, including among
younger children who may not know their HIV status or have
sole responsibility over their medication-taking. One study
among youth aged 7 to 16 years living with HIV found that
self-reported adherence, including missed doses in the past
7 days, was significantly correlated with viral load.34
This study had a number of important strengths. Electronic
adherence monitoring was used as a reference standard, as has
been done in other studies evaluating adherence assessment.13,26
Compared to adults, there are fewer data using EAM technology
among children living with HIV in resource-limited settings,
including usingMEMS to validate potential low-cost assessment
tools such as adherence questionnaires.15,26,35 These data help to
guide adherence measurement in settings where EAM is not fea-
sible. Children participating in this study were able to achieve
high rates of adherence toART,which is consistent with previous
studies we have conducted in Kenya16 as well as data published
among children living with HIV using MEMS in Uganda26 and
Zambia.15 Although the high rates of adherence among children
in sub-Saharan Africa are encouraging,36 there are few interven-
tion studies to improve adherence to ART among this popula-
tion.37 This study was also strengthened by the fact that the
adherence questionnaire was delivered by providers during rou-
tine clinical encounters with children. In discussions with provi-
ders in this setting, itwas important that theyhad a simple tool that
was both accurate and brief, as caring for a high patient load
prohibits lengthier adherence assessments in the clinic setting.
The adherence items identified as significant in this study may
be integrated into the routine clinical examination form as
screening-type questions, with patients referred for further adher-
ence assessment or counseling based on their responses.
There are a number of limitations of this study to consider.
First, convenience sampling was used to recruit participants,
which introduced potential selection bias. Although current
adherence was not considered for inclusion into the study, it is
possible that children who had poorer adherence than average or
children who had better adherence were more likely to enroll;
however, this bias would not have impacted the validation of
items. Second, although EAM is often considered the gold stan-
dard adherence measure, there are potential limitations to using
this technology that have not been adequately explored in this
population and in this setting.38,39 Misclassification bias is a
limitation whereby participants might remove more than 1 dose
from the bottle at a time (“pocket dosing” in an example of this
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misclassification) or open the bottle without actually removing
any medication (“curiosity event” is an example of this misclas-
sification). In a previous study in a different cohort of child–
caregiver dyads using MEMS in this setting, we found that most
caregivers (88%) liked having the MEMS and would recom-
mend it to others, while 21% reported that they did have con-
cerns using it including that it was noticeable, difficult to carry,
and fears of the device breaking.40 To address some of these
potential barriers, study participants were given training by study
personnel on how the MEMS device works and how to care for
it. Third, given that the participants knew that we were measur-
ing their adherence using MEMS, this could have influenced
their adherent behaviors. We did see an increase in adherence
during the course of the study, and the procedures of the protocol
likely had some positive intervention effects on patients’ level of
adherence; however, this should not have impacted the valida-
tion analysis of questionnaire items. Finally, the study design did
not allow evaluation of the effects of the questionnaire length
and the person administering the questionnaire. Providers were
trained on the administration of the questionnaire and were expe-
rienced in routine adherence monitoring, but there could have
been provider-level differences that affected the validity of the
questionnaire or individual items.
Conclusion
We provide evidence for the validity of a brief, 10-item adher-
ence questionnaire administered to caregivers of children liv-
ing with HIV on ART. Several questionnaire items related to
who gives the child medication and caregiver-reported prob-
lems giving medication were significantly and independently
associated with EAM over the course of the study, thus pro-
viding potential valuable tools for providers to quickly and
accurately screen for suboptimal adherence and identify
patients who may need further adherence evaluation and
intervention.
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